| Dr Sheila Malone Taber, DO | |
|
744 W 9th St, Tulsa, OK 74127-9020 | |
| (918) 728-6194 | |
| (918) 664-2521 |
| Full Name | Dr Sheila Malone Taber |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 27 Years |
| Location | 744 W 9th St, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447241971 | NPI | - | NPPES |
| 1000894890A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 3792 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cherokee Nation W W Hastings Indian Hospital | Tahlequah, OK | Hospital |
| St Mary's Regional Medical Center | Enid, OK | Hospital |
| Saint Francis Hospital Muskogee | Muskogee, OK | Hospital |
| Great Plains Regional Medical Center | Elk city, OK | Hospital |
| Integris Bass Baptist Health Center | Enid, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Creek Nation Hospital And Clinics | 5698786226 | 265 |
| Diagnostic Imaging Associates Inc | 8820083645 | 64 |
| Choctaw Nation Of Oklahoma | 1759294838 | 204 |
| Pawnee Indian Health Center | 2769470160 | 59 |
| Pine Ridge Indian Health Service Hospital | 4688571326 | 93 |
| Zuni Indian Hospital | 5698689644 | 57 |
| Creek Nation Hospital And Clinics | 5698786226 | 265 |
| Cherokee Nation | 5799698742 | 329 |
| Claremore Indian Hospital | 9436069911 | 109 |
News Archive
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.
Neighbors Emergency Center announces today the opening of its new El Paso, Texas center. The emergency center location will be open to receive patients at 6:00 pm MDT on Tuesday, August 18, 2015.
In the current issue of Psychotherapy and Psychosomaticsthere is news about an international group of investigators who felt that benzodiazepines are getting unwarranted bad press, compared to other psychotropic drugs.
Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).
› Verified 7 days ago
| Entity Name | Ctca Physicans Group Of Oklahoma, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053309591 PECOS PAC ID: 2163328774 Enrollment ID: O20031212000074 |
News Archive
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.
Neighbors Emergency Center announces today the opening of its new El Paso, Texas center. The emergency center location will be open to receive patients at 6:00 pm MDT on Tuesday, August 18, 2015.
In the current issue of Psychotherapy and Psychosomaticsthere is news about an international group of investigators who felt that benzodiazepines are getting unwarranted bad press, compared to other psychotropic drugs.
Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).
› Verified 7 days ago
| Entity Name | Diagnostic Imaging Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427049956 PECOS PAC ID: 8820083645 Enrollment ID: O20040420000018 |
News Archive
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.
Neighbors Emergency Center announces today the opening of its new El Paso, Texas center. The emergency center location will be open to receive patients at 6:00 pm MDT on Tuesday, August 18, 2015.
In the current issue of Psychotherapy and Psychosomaticsthere is news about an international group of investigators who felt that benzodiazepines are getting unwarranted bad press, compared to other psychotropic drugs.
Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).
› Verified 7 days ago
| Entity Name | Creek Nation Hospital & Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366593923 PECOS PAC ID: 5698786226 Enrollment ID: O20070821000130 |
News Archive
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.
Neighbors Emergency Center announces today the opening of its new El Paso, Texas center. The emergency center location will be open to receive patients at 6:00 pm MDT on Tuesday, August 18, 2015.
In the current issue of Psychotherapy and Psychosomaticsthere is news about an international group of investigators who felt that benzodiazepines are getting unwarranted bad press, compared to other psychotropic drugs.
Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).
› Verified 7 days ago
| Entity Name | Comanche County Hospital Authority Southwest Radiology |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194996447 PECOS PAC ID: 7113082009 Enrollment ID: O20090209000657 |
News Archive
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.
Neighbors Emergency Center announces today the opening of its new El Paso, Texas center. The emergency center location will be open to receive patients at 6:00 pm MDT on Tuesday, August 18, 2015.
In the current issue of Psychotherapy and Psychosomaticsthere is news about an international group of investigators who felt that benzodiazepines are getting unwarranted bad press, compared to other psychotropic drugs.
Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).
› Verified 7 days ago
| Entity Name | Landmark Cancer Center Gp Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598102345 PECOS PAC ID: 1658506662 Enrollment ID: O20131029001312 |
News Archive
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.
Neighbors Emergency Center announces today the opening of its new El Paso, Texas center. The emergency center location will be open to receive patients at 6:00 pm MDT on Tuesday, August 18, 2015.
In the current issue of Psychotherapy and Psychosomaticsthere is news about an international group of investigators who felt that benzodiazepines are getting unwarranted bad press, compared to other psychotropic drugs.
Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sheila Malone Taber, DO 4500 S Garnett Rd, Ste 300, Tulsa, OK 74146-5229 Ph: (918) 728-6194 | Dr Sheila Malone Taber, DO 744 W 9th St, Tulsa, OK 74127-9020 Ph: (918) 728-6194 |
News Archive
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.
Neighbors Emergency Center announces today the opening of its new El Paso, Texas center. The emergency center location will be open to receive patients at 6:00 pm MDT on Tuesday, August 18, 2015.
In the current issue of Psychotherapy and Psychosomaticsthere is news about an international group of investigators who felt that benzodiazepines are getting unwarranted bad press, compared to other psychotropic drugs.
Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).
› Verified 7 days ago
Jonathan Cross, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5801 E 41st St Ste 900, Tulsa, OK 74135 Phone: 918-747-4975 Fax: 918-743-8552 | |
Dr. Kim R Hauger, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5801 E 41st St Ste 900, Tulsa, OK 74135 Phone: 918-747-4975 Fax: 918-743-8552 | |
Nina Jones, MD Radiology Medicare: Medicare Enrolled Practice Location: 4500 S Garnett Rd Ste 300, Tulsa, OK 74146 Phone: 918-728-6194 | |
Dr. Leila Danielle See, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 744 W 9th St, Tulsa, OK 74127 Phone: 981-599-5031 | |
Christopher Roman, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 4500 S Garnett Rd Ste 112, Tulsa, OK 74146 Phone: 918-935-3550 | |
Dr. Phillip Osborn Flinn, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 1120 S Utica Ave, Tulsa, OK 74104 Phone: 918-934-8347 Fax: 918-917-4114 | |
Shawn D Grant, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1120 S Utica Ave, Tulsa, OK 74104 Phone: 918-579-7720 |